Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Sponsor: Janux Therapeutics
Summary
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Official title: An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2023-04-19
Completion Date
2027-10
Last Updated
2025-10-14
Healthy Volunteers
No
Conditions
Interventions
JANX008
JANX008 is dosed via IV weekly in a 21-day cycle
Locations (18)
City of Hope Medical Center
Duarte, California, United States
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
University of California San Diego Moores Cancer Center
San Diego, California, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Washington University
St Louis, Missouri, United States
Laura and Isaac Perlmutter Cancer Center NYU Langone Health
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
The Christ Hospital Cancer Center
Cincinnati, Ohio, United States
Ohio State University Hospital
Columbus, Ohio, United States
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
The University of Texas, MD Anderson Cancer Center
Houston, Texas, United States